At the 44th Annual J.P. Morgan Healthcare Conference, ANI Pharmaceuticals executives underscored the company’s shift toward rare diseases as its primary growth engine. Management projects over $1 billion in revenue for 2026, reflecting 26% growth year-over-year versus 2025, which itself delivered more than 39% revenue growth. The rare disease segment is expected to comprise approximately 60% of total revenues, driven by its lead asset, purified Cortrophin Gel, which offers durable, multiyear growth potential. Meanwhile, the company’s generics business continues to generate robust cash flows through advanced R&D capabilities, U.S. manufacturing and operational execution, creating a reinvestment cycle that supports both the rare disease pipeline and broader portfolio expansion.

ANI closed out 2025 with robust results that set the stage for an aggressive 2026 outlook. Management issued guidance for full-year 2026 revenues of $1.055 billion to $1.115 billion, representing approximately 60% growth over 2025. Purified Cortrophin Gel remains the principal driver, with sales projected between $540 million and $575 million next year. To capture market share, the company is expanding its commercial team by 90 professionals and expects Phase 4 trial data to further validate the therapy’s efficacy and support label expansion.

ANI Pharmaceuticals enters 2026 with $285 million in cash on the balance sheet and no anticipated cash burn, providing ample flexibility to fund pipeline development and potential acquisitions. At an 11.2x forward P/E multiple, the stock trades at a 43% discount to the peer group average, reflecting a valuation gap that management believes is unjustified given its growth trajectory and cash-generation profile. With a focus on high-margin rare disease products and a proven generics cash engine, ANI is positioned to deliver sustainable earnings growth and unlock shareholder value.